Comparison of different gene editing technologies.
Gene editing is a type of genetic engineering in which DNA is inserted, deleted, modified, or replaced in the genome of a living organism. Unlike traditional methods that randomly insert genetic material into a host genome, current gene editing technologies target and change the specific genome locations. Zinc finger nucleases (ZFNs), transcription activator-like effectors nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPRs)/Cas9 nuclease system are the three common gene editing technologies. These technologies have been widely used in genome engineering to enable a broad range of mutation by inducing DNA breaks that stimulate error-prone repairs such as homologous recombination (HR) or nonhomologous end joining (NHEJ). They successfully make it possible to achieve site-specific editing, modification, and manipulation at specific genomic sites (Table 1) .
|Source||Extensively exists in the nature||Plant pathogenic bacteria Xanthomonas||An adaptive immune system in bacteria|
|Targeting specificity determinant||Zinc finger protein||TALE||SgRNA|
|Nuclease||Fok I||Fok I||Cas9|
|Restriction for a target sequence||Rich in cytosine||No special restriction||PAM|
|Target site||Two (left and right)||Two (left and right)||Only one|
|Length of target gene||12–18 bp||12–18 bp||18–23 bp|
|Mode of action||Two proteins act on two target sites||Two proteins act on two target sites||RNA and Cas9 act on one target site|
|Cleavage site||DSB with a sticky end||DSB with a sticky end||DSB with a blunt end|
|Ease of engineering||Low||Medium||High|
|Ease of characterization||Low||Medium||High|
ZFNs are artificial
Transcription activator-like effectors (TALEs) are proteins secreted by bacteria Xanthomonas via type III secretion system when they infect various plant species. TALEs are important virulence factors that act as transcriptional activators in the plant cell nucleus . Each TALE contains a central repetitive region consisting of varying numbers of repeat units (about 17.5 repeats) of 34 amino acids [3, 4]. The DNA-binding domain contains a highly conserved 34 amino acid sequence with the exception of the 12th and 13th amino acids . Only the 12th and 13th amino acids in TALEs are changeable and variable, the other amino acids are constant and stable. These two locations—repeat variable di-residues (RVD) are highly variable and show a strong correlation with a specific nucleotide recognition by different frequency, for example, NI recognize A (55%), NG recognize T (50%), NN recognize G (7%), and HD recognize C(69%) . Two amino acids have known to recognize one nucleotide after the breaking of code of DNA-binding specificity of TALEs [3, 4]. The restriction endonuclease Fok I consists of an N-terminal specific DNA-binding domain and a C-terminal nonspecific DNA cleavage domain. The nonspecific DNA cleavage domain of Fok I cleaves the double-strand DNA (DSB) at a fixed distance of 9 and 13 nucleotides downstream of the recognition site . TALENs are artificial
The CRISPRs/Cas9 system, originally found in the bacteria, functions as an adaptive immune system against foreign virus or plasmid DNA. CRISPRs are DNA loci containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to the foreign DNA. CRISPR-associated protein (Cas9) is a DNA endonuclease whose structure is bilobed, composed of target recognition domain and nuclease lobes. The nuclease lobe contains nucleases RuvC, HNH, and a carboxyl-terminal domain for the protospacer adjacent motif (PAM) recognition . The Type II CRISPRs system is currently limited to target sequences that are N12-20NGG, where NGG represents the PAM sequence . Any potential target sequence must have a specific PAM sequence on its 3′ end. The CRISPR locus consists of Cas9 endonucleases, CRISPRs RNAs (crRNAs), trans-activating crRNAs (tracrRNAs), and precursor crRNAs (pre-crRNAs). tracrRNA is partially
2.1 Tools for basic research
2.1.1 Genetic cloning of living organisms
For conventional genetic cloning of animals, plants, and microbes, the target genes in the specific genome are cut using restriction enzymes. It usually takes lots of work and long time to clone and screen for the desired ones. Current gene editing technologies can be used to achieve the desired clones both quickly and accurately, without the limitation of restriction site availability .
2.1.2 Establishment of animal models
Genetic cloning, gene knock-in, and gene knockout are the most common methods to make induced or experimental animal models. The efficient approaches include ZFNs, TALENs, and CRISPRs/Cas9. By these new gene editing technologies, specific animal models of many diseases for which there are no animal models available previously have been established with unprecedented efficiency and precision [12, 13, 14].
2.1.3 Development of testing tools and reagents
CRISPRs/Cas9 can be optimized by bacterial genotypes to be more adaptive to the variation of food pathogens, compared with traditional methods. The CRISPR locus of different bacterial species show high variance to be an ideal basis for genotyping . The CRISPR/Cas12a(Cpf1) DETECTR (DNA endonuclease targeted CRISPR trans reporter) system can be used to diagnose gene mutations, cancers, and microbial infections and test microbial antibiotic resistance by analyzing specimens .
2.1.4 Discovery of drugs
The screening and identification of target sites are critical to drug discovery; thus, excellent and suitable platforms are needed. Gene editing technologies can work for the editing of functional genes and the screening of target sites. For example, CRISPRs/Cas9 was used to target the exons encoding functional protein domains. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia (AML) cells identified 6 known drug targets and 19 additional dependencies .
2.2 Nonhuman therapeutics
2.2.1 Agricultural products
The gene editing technology can be used to produce agricultural products in accordance with the need of humans. For example, crops were produced with high yield and resistant to diseases, insects, herbicides, and harsh environment [18, 19]; domesticated animals (pig, buffalo) were produced with double muscle phenotype ; and aquatic products (catfish) were produced with high level myostatin (MSTN) gene expression .
We can make food more productive or have longer shelf-life by gene editing technologies. For example, CRISPRs/Cas9 was used to edit thermophilic bacteria Streptococcus thermophilus as a bacteriophage-insensitive mutant to improve the product (e.g., yogurt, cheese) yield by refraining from the infection of phages . The white button mushroom Agaricus bisporus was engineered to resist browning using CRISPRs/Cas9. The effect was achieved by targeting to knock out the genes that encodes polyphenol oxidase—an enzyme that causes browning .
2.2.3 Industrial products
CRISPRs/Cas9 has been used to establish marine algae (e.g., diatoms) as useful in industrial applications as the carbon neutral synthesis of fuels, pharmaceuticals, health foods, biomolecules, materials related to nanotechnology, and bioremediations of contaminated water [24, 25]. CRISPRs/Cas9 was used to encode the pixel values of black and white images and a short movie into the living bacterial genomes. By CRISPRs/Cas9, the technical limits of this information storage system can be optimized to be minimal. CRISPRs/Cas9 can capture and stably store many real data within the genomes of living cells .
2.2.4 Environmental protection
Marine microalgae are in charge of about 40% of primary production on earth and capture more CO2 than rain forests. Diatoms are the most important unicellular eukaryotic microalgae and have dominant ecological significance. CRISPRs/Cas9 can be used to modify the diatom genome to achieve more effects in reducing the global warming .
2.2.5 Restoration of extinct animals
Woolly mammoths are different from current living elephants by adapting to the extreme cold environment. The mammoth TRPV3 gene, which encodes a temperature-sensitive transient receptor potential (thermoTRP) channel involved in thermal sensation and hair growth, could be achieved by modifying genes of Asian elephants . The mammoth may be restored using CRISPRs/Cas9, if the modified embryo can be successfully transferred into the uterus of living elephants.
2.3 Human therapeutics
2.3.1 Medicine screening
The therapeutic strategies of Parkinson’s disease (PD) are quite variable including drug and nondrug treatment. Therefore, it is necessary to find a suitable strategy to treat PD safely, efficiently, and quickly. A novel tool was established for monitoring endogenous alpha-synuclein (α-SYN) transcription by NanoLuc luciferase tag insertion at the 3′ end using CRISPRs/Cas9, and thus making it possible to screen for strategies rapidly that can be used for PD therapy efficiently .
2.3.2 Preparation for cell therapy or immunotherapy
The gene-editing technology can be applied to engineer induced pluripotent stem (iPS) cells and chimeric antigen receptor T (CART) cells. CRISPRs/Cas9 has been used to engineer iPS cells to evade immune rejection in full immunocompetent allogeneic recipients . Because the CD19 CAR was successfully used in treatment, CRISPRs/Cas9 may further enhance the efficacy and safety of CART cells by engineering therapeutic T cells .
2.3.3 Potential application for disease treatment
18.104.22.168 Virus latent infection
Diseases caused by viruses are difficult to treat due to their high mutation rates and latent infections. It is almost impossible to eradicate latent viruses in the human host. However, TALENs and CRISPRs/Cas9 have been found to provide good strategies in targeting viruses and limiting their productive and latent infections ex vivo and/or in vivo, such as herpes simplex virus 1 (HSV-1), Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), human immunodeficiency virus (HIV), and hepatitis B virus (HBV) [31, 32, 33, 34, 35, 36].
22.214.171.124 Genetic disease
Genetic diseases can be cured by gene therapies such as sickle cell anemia, β-thalassemia, muscular dystrophy, α1-antitrypsin deficiency, Leber congenital amaurosis, and cystic fibrosis . The gene editing technologies (e.g., CRISPRs/Cas9) potentially facilitate the progress of gene therapy, because many experiments have been successful ex vivo and in vivo, and some of them are being under clinical trials.
126.96.36.199 Neurodegenerative disease
By applying the Perturbing Regulatory Interactions by Synthetic Modulators (PRISM) to a yeast model of PD, sgRNAs were identified to modulate transcriptional networks and protect cells from α-Syn toxicity . The APPswe (Swedish) mutation in the amyloid precursor protein (APP) gene causes Alzheimer’s disease (AD). The mutant APPSW allele can be selectively disrupted using CRISPRs/Cas9 both ex vivo and in vivo and thereby decrease pathogenic amyloid-β (Aβ) .
CRISPRs/Cas9 were tried to inhibit hepatocellular carcinoma (HCC). miR-125b can suppress the expression of SIRT6 by directly targeting the seed-matching region of its 3′UTR. After the expression of SIRT6 knocked out through CRISPRs/Cas9, HCC cells showed the decreased viability and invasiveness, which had the similar function upon the overexpression of the miR-125b . CRISPRs/Cas9 was also tried to inhibit breast cancer. Cyclin-dependent kinases (CDKs) are established anti-cancer drug targets, and a new generation of CDK inhibitors provides clinical benefits to the patients. Breast cancer cells were genetically manipulated using a deactivated CRISPRs/Cas9 (dCRISPR) approach to strengthen the endogenous CDK18 promoter to express highly to exhibit an increased sensitivity .
The gene editing technologies, especially CRISPRs/Cas9, have been extensively used as tools in basic research for genome encoding, silencing, enhancing, and modification. Currently, they are further applied in manufacturing nonhuman therapeutic products and medicinal products. Particularly, the discovery of medicinal products using gene editing technologies will open a new era for human therapeutics and expect to bring a hope for patient recovery from being seriously sick. Many biotechnology companies and pharmaceutical plants have successfully produced products using gene editing technologies. For example, CRISPR has become an industry which is prosperously developing recently. Nonhuman therapeutic products are usually manufactured nonexclusively, while human therapeutic products are manufactured exclusively because they are highly technical, ethically concerned, and more profitable. Gene editing technologies are very promising in applications, though there are still many technical (e.g., off target effects, option of delivery tools, localization of function) and ethical challenges (e.g., evaluation of benefits and risks, compatibility of private interests and the public good, random manipulation of genes, commercialization of human therapy) unsolved. More and more products based on these technologies are approved for marketing. We also expect the challenges of safety concerns (e.g., genetically modified organism, tumorigenesis, etc.) and ethical issues will be overcome in the near future.